Haenni A, Lithell H
Department of Public Health and Caring Sciences/Geriatrics, Uppsala, Sweden.
J Hypertens Suppl. 1999 Aug;17(3):S29-35.
To study whether insulin sensitivity and insulin response are altered by moxonidine treatment in obese patients with mild essential hypertension.
a prospective, double-blind, placebo-controlled, randomized, parallel group study.
77 patients with mild essential hypertension and body mass index > 27 were enrolled. A placebo run-in period of 1-3 weeks was followed by 8-9 weeks of double-blind treatment with either placebo or moxonidine. Patients receiving antihypertensive drugs underwent a 4-week wash-out period preceeding the placebo run-in. Insulin sensitivity was evaluated by hyperinsulinaemic euglycaemic clamp test. Insulin response was measured during intravenous glucose tolerance test.
72 patients completed the study. No serious adverse events were reported. The glucose infusion rate (M value), and insulin sensitivity index (M/I ratio) increased in the moxonidine-treated subjects by 10% (P = 0.025), and 11% (P = 0.04), respectively, whereas the values in the placebo group remained unchanged. In the predefined insulin-resistant subgroup with M/I ratio < 3.6 at baseline, glucose infusion rate and insulin sensitivity index increased by 21% whereas values in the placebo group remained unchanged. A between-group comparison showed a statistical significant difference in the M value (P = 0.026) and a borderline statistical difference in the M/I ratio (P = 0.056) in favour of moxonidine. No statistically significant effects were seen in the subgroup with a M/I ratio > or = or 3.6 at baseline. The insulin secretion in response to glucose stimulation was unaffected in insulin-resistant as well as in insulin-sensitive hypertensive patients.
Moxonidine treatment improved insulin sensitivity in insulin-resistant, obese patients with mild hypertension, but not in insulin-sensitive obese subjects with mild hypertension, when compared to placebo. Insulin response to glucose stimulation was unaffected. The drug was well tolerated.
研究莫索尼定治疗对轻度原发性高血压肥胖患者胰岛素敏感性和胰岛素反应的影响。
一项前瞻性、双盲、安慰剂对照、随机平行组研究。
纳入77例轻度原发性高血压且体重指数>27的患者。在1 - 3周的安慰剂导入期后,进行8 - 9周的安慰剂或莫索尼定双盲治疗。接受抗高血压药物治疗的患者在安慰剂导入期前有4周的洗脱期。通过高胰岛素正常血糖钳夹试验评估胰岛素敏感性。在静脉葡萄糖耐量试验期间测量胰岛素反应。
72例患者完成研究。未报告严重不良事件。莫索尼定治疗组的葡萄糖输注率(M值)和胰岛素敏感性指数(M/I比值)分别增加了10%(P = 0.025)和11%(P = 0.04),而安慰剂组的值保持不变。在基线时M/I比值<3.6的预定义胰岛素抵抗亚组中,葡萄糖输注率和胰岛素敏感性指数增加了21%,而安慰剂组的值保持不变。组间比较显示,M值有统计学显著差异(P = 0.026),M/I比值有临界统计学差异(P = 0.056),支持莫索尼定。在基线时M/I比值≥3.6的亚组中未观察到统计学显著影响。在胰岛素抵抗和胰岛素敏感的高血压患者中,葡萄糖刺激后的胰岛素分泌均未受影响。
与安慰剂相比,莫索尼定治疗可改善胰岛素抵抗的轻度高血压肥胖患者的胰岛素敏感性,但对胰岛素敏感的轻度高血压肥胖患者无效。葡萄糖刺激后的胰岛素反应未受影响。该药物耐受性良好。